Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 548

1.

The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory.

Franzmeier N, Rubinski A, Neitzel J, Ewers M; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Nat Commun. 2019 Apr 16;10(1):1766. doi: 10.1038/s41467-019-09564-5.

2.

Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers.

Stewart T, Shi M, Mehrotra A, Aro P, Soltys D, Kerr KF, Zabetian CP, Peskind ER, Taylor P, Shaw LM, Trojanowski JQ, Zhang J; and from the Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2019 Apr 1. doi: 10.3233/JAD-190069. [Epub ahead of print]

PMID:
30958379
3.

A blood-based signature of cerebrospinal fluid Aβ1-42 status.

Goudey B, Fung BJ, Schieber C, Faux NG; Alzheimer’s Disease Metabolomics Consortium; Alzheimer’s Disease Neuroimaging Initiative.

Sci Rep. 2019 Mar 11;9(1):4163. doi: 10.1038/s41598-018-37149-7.

4.

Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease.

Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, Wang G, Graham DL, Shaw LM, Trojanowski JQ, Hassenstab JJ, Benzinger TLS, Cruchaga C, Jucker M, Levin J, Chhatwal JP, Noble JM, Ringman JM, Graff-Radford NR, Holtzman DM, Ladenson JH, Morris JC, Bateman RJ, Xiong C, Fagan AM; Dominantly Inherited Alzheimer Network.

Alzheimers Dement. 2019 Mar 4. pii: S1552-5260(19)30013-5. doi: 10.1016/j.jalz.2018.12.019. [Epub ahead of print]

PMID:
30846386
5.

Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau).

Gibbons GS, Kim SJ, Robinson JL, Changolkar L, Irwin DJ, Shaw LM, Lee VM, Trojanowski JQ.

Acta Neuropathol Commun. 2019 Mar 4;7(1):34. doi: 10.1186/s40478-019-0687-5.

6.

DirtyGenes: testing for significant changes in gene or bacterial population compositions from a small number of samples.

Shaw LM, Blanchard A, Chen Q, An X, Davies P, Tötemeyer S, Zhu YG, Stekel DJ.

Sci Rep. 2019 Feb 20;9(1):2373. doi: 10.1038/s41598-019-38873-4.

7.

Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics.

Varatharajah Y, Ramanan VK, Iyer R, Vemuri P; Alzheimer’s Disease Neuroimaging Initiative.

Sci Rep. 2019 Feb 19;9(1):2235. doi: 10.1038/s41598-019-38793-3.

8.

Predicting Alzheimer's disease progression using multi-modal deep learning approach.

Lee G, Nho K, Kang B, Sohn KA, Kim D; for Alzheimer’s Disease Neuroimaging Initiative.

Sci Rep. 2019 Feb 13;9(1):1952. doi: 10.1038/s41598-018-37769-z.

9.

The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction.

Berger M, Oyeyemi D, Olurinde MO, Whitson HE, Weinhold KJ, Woldorff MG, Lipsitz LA, Moretti E, Giattino CM, Roberts KC, Zhou J, Bunning T, Ferrandino M, Scheri RP, Cooter M, Chan C, Cabeza R, Browndyke JN, Murdoch DM, Devinney MJ, Shaw LM, Cohen HJ, Mathew JP; INTUIT Investigators.

J Am Geriatr Soc. 2019 Apr;67(4):794-798. doi: 10.1111/jgs.15770. Epub 2019 Jan 23.

PMID:
30674067
10.

Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.

Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Schlepckow K, Araque Caballero MÁ, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E, Levin J, Deming Y, Piccio L, Karch CM, Cruchaga C, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C; Alzheimer’s Disease Neuroimaging Initiative.

Mol Neurodegener. 2019 Jan 10;14(1):1. doi: 10.1186/s13024-018-0301-5.

11.

The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.

Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun-Turgut D, Poston K, Arnedo V, Frasier M, Sherer T; Parkinson's Progression Markers Initiative.

Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477. doi: 10.1002/acn3.644. eCollection 2018 Dec.

12.

Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.

Olsson B, Portelius E, Cullen NC, Sandelius Å, Zetterberg H, Andreasson U, Höglund K, Irwin DJ, Grossman M, Weintraub D, Chen-Plotkin A, Wolk D, McCluskey L, Elman L, Shaw LM, Toledo JB, McBride J, Hernandez-Con P, Lee VM, Trojanowski JQ, Blennow K.

JAMA Neurol. 2018 Dec 3. doi: 10.1001/jamaneurol.2018.3746. [Epub ahead of print]

PMID:
30508027
13.

Current state of Alzheimer's fluid biomarkers.

Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, Fagan AM, Hampel H, Mielke MM, Mikulskis A, O'Bryant S, Scheltens P, Sevigny J, Shaw LM, Soares HD, Tong G, Trojanowski JQ, Zetterberg H, Blennow K.

Acta Neuropathol. 2018 Dec;136(6):821-853. doi: 10.1007/s00401-018-1932-x. Epub 2018 Nov 28. Review.

14.

CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline.

Suárez-Calvet M, Capell A, Araque Caballero MÁ, Morenas-Rodríguez E, Fellerer K, Franzmeier N, Kleinberger G, Eren E, Deming Y, Piccio L, Karch CM, Cruchaga C, Paumier K, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Jucker M, Masters CL, Rossor MN, Ringman JM, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C; Dominantly Inherited Alzheimer Network; Alzheimer's Disease Neuroimaging Initiative.

EMBO Mol Med. 2018 Dec;10(12). pii: e9712. doi: 10.15252/emmm.201809712.

15.

Derivation of cutoffs for the Elecsys® amyloid β (1-42) assay in Alzheimer's disease.

Shaw LM, Waligorska T, Fields L, Korecka M, Figurski M, Trojanowski JQ, Eichenlaub U, Wahl S, Quan M, Pontecorvo MJ, Lachno DR, Talbot JA, Andersen SW, Siemers ER, Dean RA.

Alzheimers Dement (Amst). 2018 Aug 11;10:698-705. doi: 10.1016/j.dadm.2018.07.002. eCollection 2018.

16.

Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia.

Schilling LP, Pascoal TA, Zimmer ER, Mathotaarachchi S, Shin M, de Mello Rieder CR, Gauthier S, Palmini A, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.

Mol Neurobiol. 2018 Nov 9. doi: 10.1007/s12035-018-1405-1. [Epub ahead of print]

PMID:
30414086
17.

Distinct White Matter Changes Associated with Cerebrospinal Fluid Amyloid-β1-42 and Hypertension.

Al-Janabi OM, Brown CA, Bahrani AA, Abner EL, Barber JM, Gold BT, Goldstein LB, Murphy RR, Nelson PT, Johnson NF, Shaw LM, Smith CD, Trojanowski JQ, Wilcock DM, Jicha GA.

J Alzheimers Dis. 2018;66(3):1095-1104. doi: 10.3233/JAD-180663.

18.

Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers.

Nho K, Kueider-Paisley A, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, Blach C, Baillie R, Han X, Kastenmüller G, Jia W, Xie G, Ahmad S, Hankemeier T, van Duijn CM, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, Saykin AJ, Kaddurah-Daouk R; Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium.

Alzheimers Dement. 2019 Feb;15(2):232-244. doi: 10.1016/j.jalz.2018.08.012. Epub 2018 Oct 15.

19.

Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome.

MahmoudianDehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xie G, Louie G, Kueider-Paisley A, Moseley MA, Thompson JW, St John Williams L, Tenenbaum JD, Blach C, Baillie R, Han X, Bhattacharyya S, Toledo JB, Schafferer S, Klein S, Koal T, Risacher SL, Kling MA, Motsinger-Reif A, Rotroff DM, Jack J, Hankemeier T, Bennett DA, De Jager PL, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, van Duijn CM, Saykin AJ, Kastenmüller G, Kaddurah-Daouk R; Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium.

Alzheimers Dement. 2019 Jan;15(1):76-92. doi: 10.1016/j.jalz.2018.07.217. Epub 2018 Oct 15. Erratum in: Alzheimers Dement. 2019 Apr;15(4):604.

20.

Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference.

Young AL, Marinescu RV, Oxtoby NP, Bocchetta M, Yong K, Firth NC, Cash DM, Thomas DL, Dick KM, Cardoso J, van Swieten J, Borroni B, Galimberti D, Masellis M, Tartaglia MC, Rowe JB, Graff C, Tagliavini F, Frisoni GB, Laforce R Jr, Finger E, de Mendonça A, Sorbi S, Warren JD, Crutch S, Fox NC, Ourselin S, Schott JM, Rohrer JD, Alexander DC; Genetic FTD Initiative (GENFI); Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Nat Commun. 2018 Oct 15;9(1):4273. doi: 10.1038/s41467-018-05892-0.

Supplemental Content

Loading ...
Support Center